![]() ![]() Trading volume hit 470 million in that single session alone, as investors speculated about the positive benefit to Endo. Wade, and traders flooded into Endo International shares. That move came after the Supreme Court overturned Roe v. On June 28, shares erupted 114% at one point and closed higher by 85%. These conversations will most likely end with a Chapter 11 filing.įor its part, ENDP stock has been all over the map for the past few months. While Endo denies these allegations, bankruptcy conversations are in full effect between the company and senior lenders. The company allegedly helped fuel the opioid crisis and is now facing thousands of lawsuits as a result. Bankruptcy Code by Endo International plc and substantially all of its subsidiaries, which could occur imminently.” “In light of the progress to date, the Company expects that these negotiations will likely result in a pre-arranged filing under Chapter 11 of the U.S. However, revenue still sank about 20% year-over-year, while Endo ended the quarter with $1.2 billion in unrestricted cash and $8.1 billion of debt. A loss of 3 cents per share beat expectations by 11 cents, while revenue of about $569 million blew past estimates by $44.5 million. On the surface, Endo International seems to have reported a solid second-quarter. ![]() More specifically, management’s warning that a bankruptcy filing could be imminent is spooking investors. What’s triggering the recent selling pressure? Technically, it was the company’s earnings report. That won’t happen unless ENDP stock falls even further from Tuesday’s current low of 36 cents. Surprisingly, though, shares are not making new 2022 lows. Shares of ENDP stock are down more than 40% today and almost 60% from last week’s high. ![]() Good luck.It hasn’t been a good run for Endo International (NASDAQ: ENDP), and Tuesday isn’t making it any better. You can also do your due diligence and share thoughts. So a 2x pe for a company with increased sales? Settled litigation? I do hope the market shakes off the fear from litigation, which was settled, and sees the earnings shine. What I like the most is they raised guidance and said margins will be close to 72% (meds are super profitable!) They grew sales by 4% beating sales estimates by 48 million. They came in at 65 cents a share beating by 16 cents!!! They made $152 million in 3 months (giving you an idea of these cash cows and how a 35 million settlement is great!) The next catalyst is today's blow out earnings. I believe is a reason for panic/fear and a sell off. Some analysts actually dropped coverage while the case was in trial. Why the stock did not take off yesterday I am clueless. Then 2 days after the thought, the 35 million in principal was thrown around, the stock took off to near 5.90.Yesterday the 35 million was finalized and to me, that is a huge whewy, discount. ![]() The stock went from 3 to 4.75 in the same day. About 2 weeks ago the idea of a settlement was aired. it took a nose dive under 3 in July with the trial going on. Take a look at the stock in June trading above 6. It was thought when the case began we would see 200-500 million settlement. The main catalyst in my eyes in the litigation settlement that was finalized for $35 million between 28 plaintiffs for the opioid crisis. In 2014 this same stock was trading near $100 a share! The company does not have the same sales or earnings power as before but they are in the right trajectory. Unfortunately they make Percocet the opioid which is in constant litigation. They have together with name brand and generics over 200 different medications and are very profitable. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |